Cargando…

Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes

BACKGROUND: Conventional chondrosarcomas are malignant cartilage tumors considered radioresistant. Nevertheless, retrospective series show a small but significant survival benefit for patients with locally advanced disease treated with radiotherapy. And, in daily practice when considered inoperable...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, Yvonne, Ingola, Martha, Briaire-de Bruijn, Inge H., Kruisselbrink, Alwine B., Venneker, Sanne, Palubeckaite, Ieva, Heijs, Bram P. A. M., Cleton-Jansen, Anne-Marie, Haas, Rick L. M., Bovée, Judith V. M. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540537/ https://www.ncbi.nlm.nih.gov/pubmed/31160965 http://dx.doi.org/10.1186/s13569-019-0119-0

Ejemplares similares

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
por: Venneker, Sanne, et al.
Publicado: (2020)

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

Selection of Effective Therapies Using Three-Dimensional in vitro Modeling of Chondrosarcoma
por: Palubeckaitė, Ieva, et al.
Publicado: (2020)

A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target
por: Franceschini, Natasja, et al.
Publicado: (2021)

Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression
por: Franceschini, Natasja, et al.
Publicado: (2021)

SUMOylation Is Associated with Aggressive Behavior in Chondrosarcoma of Bone
por: Kroonen, Jessie S., et al.
Publicado: (2021)

Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic “Stromal” Cells from Giant Cell Tumors of Bone
por: Venneker, Sanne, et al.
Publicado: (2022)

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival
por: de Jong, Yvonne, et al.
Publicado: (2019)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
por: Peterse, Elisabeth F. P., et al.
Publicado: (2016)

Targeting survivin as a potential new treatment for chondrosarcoma of bone
por: de Jong, Y, et al.
Publicado: (2016)

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway
por: Addie, Ruben D., et al.
Publicado: (2019)

IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
por: Cleven, Arjen H. G., et al.
Publicado: (2017)

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
por: Suijker, Johnny, et al.
Publicado: (2015)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Transformed Canine and Murine Mesenchymal Stem Cells as a Model for Sarcoma with Complex Genomics
por: Franceschini, Natasja, et al.
Publicado: (2021)

Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies
por: Kostine, Marie, et al.
Publicado: (2017)

Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro
por: Schrage, Yvonne M, et al.
Publicado: (2009)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo
por: Meijer, Danielle, et al.
Publicado: (2011)

Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option
por: Willems, Stefan M, et al.
Publicado: (2010)

Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma
por: Venneker, Sanne, et al.
Publicado: (2019)

BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors
por: Boeuf, Stephane, et al.
Publicado: (2012)

Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours
por: Cleven, Arjen H. G., et al.
Publicado: (2022)

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
por: van Oosterwijk, Jolieke G, et al.
Publicado: (2012)

Histological response to radiotherapy is an early event in myxoid liposarcoma
por: Lam, Suk Wai, et al.
Publicado: (2023)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors: A Common Genomic Abnormality in Vascular Malformation/Hemangioma and Simple Bone Cyst
por: Ong, Sheena L.M., et al.
Publicado: (2021)

Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma
por: Lam, Suk Wai, et al.
Publicado: (2019)

High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth()()
por: de Graaff, Marieke A., et al.
Publicado: (2017)

Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas
por: van IJzendoorn, David G. P., et al.
Publicado: (2019)

Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis
por: Lam, Suk Wai, et al.
Publicado: (2019)

Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma
por: Olsson, Linda, et al.
Publicado: (2011)

High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas
por: Lou, Sha, et al.
Publicado: (2016)

Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation
por: de Andrea, Carlos E., et al.
Publicado: (2011)

Correction: Clonal Evolution through Loss of Chromosomes and Subsequent Polyploidization in Chondrosarcoma
por: Olsson, Linda, et al.
Publicado: (2011)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013
por: van Maldegem, Annemiek M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3gn4qagfgsov5fhpiodtv8qh0c